Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T cells, raised $229 million in an upsized IPO by offering 5.5 million ADSs (all primary) at $41.50. The Paris, France-based company had planned to offer 4.8 million ADSs, upwardly revised from the originally planned 3.5 million ADSs. At its $41.50 offer price, Cellectis commands a fully diluted market cap of $1.5 billion.Cellectis will list on the NASDAQ under the symbol CLLS. BofA Merrill Lynch, Jefferies & Co. and Piper Jaffray acted as joint bookrunners on the deal.
